Limits...
Upregulated PD-1 Expression Is Associated with the Development of Systemic Lupus Erythematosus, but Not the PD-1.1 Allele of the PDCD1 Gene.

Jiao Q, Liu C, Yang Z, Ding Q, Wang M, Li M, Zhu T, Qian H, Li W, Tu N, Fang F, Ye L, Zhao Z, Qian Q - Int J Genomics (2014)

Bottom Line: The PD-1 expression levels of SLE patients were significantly increased compared with those of the healthy controls.The upregulated PD-1 expression levels in SLE patients were greatly associated with SLEDAI scores.No significant difference was found between PD-1 expression levels and SNP rs36084323.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, The First Affiliated Hospital of Soochow University, 188 Shizi Road, Suzhou 215006, China.

ABSTRACT
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with complicated genetic inheritance. Programmed death 1 (PD-1), a negative T cell regulator to maintain peripheral tolerance, induces negative signals to T cells during interaction with its ligands and is therefore a candidate gene in the development of SLE. In order to examine whether expression levels of PD-1 contribute to the pathogenesis of SLE, 30 patients with SLE and 30 controls were recruited and their PD-1 expression levels in peripheral blood mononuclear cells (PBMCs) were measured via flow cytometry and quantitative real-time-reverse transcription polymerase chain reaction (RT-PCR). Also, whether PD-1 expression levels are associated with the variant of the SNP rs36084323 and the SLE Disease Activity Index (SLEDAI) was studied in this work. The PD-1 expression levels of SLE patients were significantly increased compared with those of the healthy controls. The upregulated PD-1 expression levels in SLE patients were greatly associated with SLEDAI scores. No significant difference was found between PD-1 expression levels and SNP rs36084323. The results suggest that increased expression of PD-1 may correlate with the pathogenesis of SLE, upregulated PD-1 expression may be a biomarker for SLE diagnosis, and PD-1 inhibitor may be useful to SLE treatment.

No MeSH data available.


Related in: MedlinePlus

Increased basal programmed death 1 (PD-1) expression in PBMCs from SLE patients. (a) Representative flow cytometry analysis of PD-1 expression on CD4+, CD8+, and CD56+ T cells in SLE patients and normal healthy controls (NC); (b) upregulated expression of PD-1 on CD4+, CD8+, and CD56+ T cells from SLE patients, as compared with those from NC; (c) mRNA expression of PD-1 in PBMCs from SLE patients. Horizontal bars indicate the mean ± SD.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4016872&req=5

fig1: Increased basal programmed death 1 (PD-1) expression in PBMCs from SLE patients. (a) Representative flow cytometry analysis of PD-1 expression on CD4+, CD8+, and CD56+ T cells in SLE patients and normal healthy controls (NC); (b) upregulated expression of PD-1 on CD4+, CD8+, and CD56+ T cells from SLE patients, as compared with those from NC; (c) mRNA expression of PD-1 in PBMCs from SLE patients. Horizontal bars indicate the mean ± SD.

Mentions: Initially PD-1 protein and mRNA expression levels in all PBMCs samples were examined by flow cytometry and real-time RT-PCR. Flow cytometry analysis results demonstrated that the mean fluorescence intensity (MFI) of PD-1 was higher on CD4+ T cells, CD8+ T cells, and CD56+ T cells from PB samples of SLE patients compared to those of controls (Figures 1(a) and 1(b)). In addition, it is shown that the mean PD-1 mRNA expression levels increased in SLE patients' samples compared with controls' (Figure 1(c)).


Upregulated PD-1 Expression Is Associated with the Development of Systemic Lupus Erythematosus, but Not the PD-1.1 Allele of the PDCD1 Gene.

Jiao Q, Liu C, Yang Z, Ding Q, Wang M, Li M, Zhu T, Qian H, Li W, Tu N, Fang F, Ye L, Zhao Z, Qian Q - Int J Genomics (2014)

Increased basal programmed death 1 (PD-1) expression in PBMCs from SLE patients. (a) Representative flow cytometry analysis of PD-1 expression on CD4+, CD8+, and CD56+ T cells in SLE patients and normal healthy controls (NC); (b) upregulated expression of PD-1 on CD4+, CD8+, and CD56+ T cells from SLE patients, as compared with those from NC; (c) mRNA expression of PD-1 in PBMCs from SLE patients. Horizontal bars indicate the mean ± SD.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4016872&req=5

fig1: Increased basal programmed death 1 (PD-1) expression in PBMCs from SLE patients. (a) Representative flow cytometry analysis of PD-1 expression on CD4+, CD8+, and CD56+ T cells in SLE patients and normal healthy controls (NC); (b) upregulated expression of PD-1 on CD4+, CD8+, and CD56+ T cells from SLE patients, as compared with those from NC; (c) mRNA expression of PD-1 in PBMCs from SLE patients. Horizontal bars indicate the mean ± SD.
Mentions: Initially PD-1 protein and mRNA expression levels in all PBMCs samples were examined by flow cytometry and real-time RT-PCR. Flow cytometry analysis results demonstrated that the mean fluorescence intensity (MFI) of PD-1 was higher on CD4+ T cells, CD8+ T cells, and CD56+ T cells from PB samples of SLE patients compared to those of controls (Figures 1(a) and 1(b)). In addition, it is shown that the mean PD-1 mRNA expression levels increased in SLE patients' samples compared with controls' (Figure 1(c)).

Bottom Line: The PD-1 expression levels of SLE patients were significantly increased compared with those of the healthy controls.The upregulated PD-1 expression levels in SLE patients were greatly associated with SLEDAI scores.No significant difference was found between PD-1 expression levels and SNP rs36084323.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, The First Affiliated Hospital of Soochow University, 188 Shizi Road, Suzhou 215006, China.

ABSTRACT
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with complicated genetic inheritance. Programmed death 1 (PD-1), a negative T cell regulator to maintain peripheral tolerance, induces negative signals to T cells during interaction with its ligands and is therefore a candidate gene in the development of SLE. In order to examine whether expression levels of PD-1 contribute to the pathogenesis of SLE, 30 patients with SLE and 30 controls were recruited and their PD-1 expression levels in peripheral blood mononuclear cells (PBMCs) were measured via flow cytometry and quantitative real-time-reverse transcription polymerase chain reaction (RT-PCR). Also, whether PD-1 expression levels are associated with the variant of the SNP rs36084323 and the SLE Disease Activity Index (SLEDAI) was studied in this work. The PD-1 expression levels of SLE patients were significantly increased compared with those of the healthy controls. The upregulated PD-1 expression levels in SLE patients were greatly associated with SLEDAI scores. No significant difference was found between PD-1 expression levels and SNP rs36084323. The results suggest that increased expression of PD-1 may correlate with the pathogenesis of SLE, upregulated PD-1 expression may be a biomarker for SLE diagnosis, and PD-1 inhibitor may be useful to SLE treatment.

No MeSH data available.


Related in: MedlinePlus